Document is current
Any future updates will be listed below
-
Authors
Lareau, Caleb A. https://orcid.org/0000-0003-4179-4807
Liu, Vincent https://orcid.org/0000-0002-6790-6603
Muus, Christoph
Praktiknjo, Samantha D. https://orcid.org/0000-0002-0186-5271
Nitsch, Lena
Kautz, Pauline https://orcid.org/0000-0002-9658-1676
Sandor, Katalin https://orcid.org/0000-0003-2892-4865
Yin, Yajie https://orcid.org/0000-0002-2220-005X
Gutierrez, Jacob C.
Pelka, Karin https://orcid.org/0000-0003-2856-8602
Satpathy, Ansuman T. https://orcid.org/0000-0002-5167-537X
Regev, Aviv
Sankaran, Vijay G. https://orcid.org/0000-0003-0044-443X
Ludwig, Leif S. https://orcid.org/0000-0002-2916-2164
- License Information
-
More Information
Article History
Received: 8 March 2022
Accepted: 11 November 2022
First Online: 15 February 2023
Competing interests
: The Broad Institute has filed a patent relating to the use of the technology described in this paper for which C.A.L., L.S.L., C.M., A.R. and V.G.S. are named as inventors (US Patent App. 17/251,451). A.R. is a founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas Therapeutics and until 31 August 2020, was a scientific advisory board member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov and Thermo Fisher Scientific. From 1 August 2020, A.R. has been an employee of Genentech. V.G.S. serves as an advisor to and/or has equity in Novartis, Forma, Cellarity, Ensoma and Polaris Partners. A.T.S. is a founder of Immunai and Cartography Biosciences and receives research funding from Merck Research Laboratories and Allogene Therapeutics.
